Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs WOCKHARDT - Comparison Results

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES WOCKHARDT ALKEM LABORATORIES/
WOCKHARDT
 
P/E (TTM) x 24.5 -88.9 - View Chart
P/BV x 5.9 2.0 300.2% View Chart
Dividend Yield % 0.8 0.0 41,887.6%  

Financials

 ALKEM LABORATORIES   WOCKHARDT
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
WOCKHARDT
Mar-18
ALKEM LABORATORIES/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs2,7201,012 268.8%   
Low Rs1,660532 312.4%   
Sales per share (Unadj.) Rs697.9355.9 196.1%  
Earnings per share (Unadj.) Rs96.1-60.3 -159.5%  
Cash flow per share (Unadj.) Rs117.3-46.8 -250.8%  
Dividends per share (Unadj.) Rs25.000.01 250,000.0%  
Dividend yield (eoy) %1.10 88,092.3%  
Book value per share (Unadj.) Rs515.2257.8 199.9%  
Shares outstanding (eoy) m119.57110.63 108.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.12.2 144.7%   
Avg P/E ratio x22.8-12.8 -178.0%  
P/CF ratio (eoy) x18.7-16.5 -113.2%  
Price / Book Value ratio x4.33.0 142.0%  
Dividend payout %26.00 -156,776.3%   
Avg Mkt Cap Rs m261,87985,379 306.7%   
No. of employees `00014.36.3 229.1%   
Total wages/salary Rs m15,0559,371 160.7%   
Avg. sales/employee Rs Th5,822.66,295.0 92.5%   
Avg. wages/employee Rs Th1,050.51,498.3 70.1%   
Avg. net profit/employee Rs Th802.0-1,066.3 -75.2%   
INCOME DATA
Net Sales Rs m83,44439,369 212.0%  
Other income Rs m1,0421,202 86.7%   
Total revenues Rs m84,48640,571 208.2%   
Gross profit Rs m14,73418 80,513.1%  
Depreciation Rs m2,5281,495 169.0%   
Interest Rs m6512,555 25.5%   
Profit before tax Rs m12,598-2,830 -445.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m1,105257 429.9%   
Profit after tax Rs m11,493-6,669 -172.3%  
Gross profit margin %17.70 37,986.4%  
Effective tax rate %8.8-9.1 -96.6%   
Net profit margin %13.8-16.9 -81.3%  
BALANCE SHEET DATA
Current assets Rs m54,96033,796 162.6%   
Current liabilities Rs m32,43326,917 120.5%   
Net working cap to sales %27.017.5 154.5%  
Current ratio x1.71.3 135.0%  
Inventory Days Days8079 100.3%  
Debtors Days Days7289 80.9%  
Net fixed assets Rs m32,71039,664 82.5%   
Share capital Rs m239553 43.2%   
"Free" reserves Rs m61,36827,968 219.4%   
Net worth Rs m61,60728,522 216.0%   
Long term debt Rs m1,59221,731 7.3%   
Total assets Rs m99,43381,620 121.8%  
Interest coverage x20.4-0.1 -18,939.5%   
Debt to equity ratio x00.8 3.4%  
Sales to assets ratio x0.80.5 174.0%   
Return on assets %12.2-5.0 -242.3%  
Return on equity %18.7-23.4 -79.8%  
Return on capital %21.0-7.7 -273.2%  
Exports to sales %19.10-   
Imports to sales %3.00-   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,0619,807 163.8%   
Fx outflow Rs m2,4831,789 138.8%   
Net fx Rs m13,5788,019 169.3%   
CASH FLOW
From Operations Rs m5,851684 854.9%  
From Investments Rs m-7,4146,302 -117.6%  
From Financial Activity Rs m792-7,695 -10.3%  
Net Cashflow Rs m-731-664 110.1%  

Share Holding

Indian Promoters % 66.9 74.5 89.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 2.3 1,439.1%  
FIIs % 0.0 7.7 -  
ADR/GDR % 0.0 0.1 -  
Free float % 0.0 15.4 -  
Shareholders   68,381 67,757 100.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   CIPLA  PIRAMAL ENTERPRISES  NATCO PHARMA  SHASUN PHARMA  PFIZER  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 470 Points Lower; Tata Motors & Tata Steel Fall 6%(Closing)

Indian share markets witnessed huge selling pressure today, in line with global equities and fell on to bearish territory.

Related Views on News

ASTRAZENECA PHARMA Share Price Down by 5%; BSE HEALTHCARE Index Down 2.5% (Market Updates)

Jan 18, 2021 | Updated on Jan 18, 2021

ASTRAZENECA PHARMA share price is trading down by 5% and its current market price is Rs 4,200. The BSE HEALTHCARE is down by 2.5%. The top gainers in the BSE HEALTHCARE Index are GSK PHARMA (up 1.2%) and IPCA LABS (up 1.0%). The top losers are ASTRAZENECA PHARMA (down 5.3%) and WOCKHARDT (down 5.2%).

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 18, 2021 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - ASTRAZENECA PHARMA COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS